HCV Gene Therapy

RAd May Be Useful for HCV Vaccine/Treatment

Published in Vaccine Weekly, March 10th, 1997

Replication-defective recombinant adenoviruses can efficiently express hepatitis C virus (HCV) proteins and are able to induce an in vivo cytotoxic T-cell response against a diversity of epitopes from HCV antigens, according to a European multicenter report.

"These vectors should be taken into consideration in the design of vaccines and also as a means to stimulate specific T-cell responses in chronic HCV carriers," Oscar Bruna-Romero and colleagues wrote ("Induction of Cytotoxic T-Cell Response Against HCV Structural Antigens Using a Defective Recombinant Adenovirus," Hepatology, February 1997;25(2):470-477).

HCV infection has a strong tendency to...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (1997-03-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry